Dual Antiplatelet Therapy or Dual Pathway Inhibition

Shinya Goto; Shinichi Goto

doi:10.1055/a-2191-7627

Thrombosis and Haemostasis, Table of Contents

Thromb Haemost 2024; 124(03): 274-276
DOI: 10.1055/a-2191-7627

Invited Editorial Focus

Dual Antiplatelet Therapy or Dual Pathway Inhibition

Shinya Goto

¹Department of Medicine (Cardiology), Department of General Medicine, Tokai University School of Medicine, Isehara, Japan

,

Shinichi Goto

¹Department of Medicine (Cardiology), Department of General Medicine, Tokai University School of Medicine, Isehara, Japan

› Author Affiliations

Abstract

Full Text

References

References
1 Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (Second International Study of Infarct Survival) Collaborative Group. Lancet 1988; 2 (8607) 349-360
2 Tamura N, Kitajima I, Kawamura Y. et al. Important regulatory role of activated platelet-derived procoagulant activity in the propagation of thrombi formed under arterial blood flow conditions. Circ J 2009; 73 (03) 540-548
3 Goto S. Vascular engineering of blood coagulation. In: Tanishita K, Yamamoto K. eds. Vascular Engineering. Tokyo: Springer; 2016: 211-219
4 Patrono C, García Rodríguez LA, Landolfi R, Baigent C. Low-dose aspirin for the prevention of atherothrombosis. N Engl J Med 2005; 353 (22) 2373-2383
5 Khan SU, Singh M, Valavoor S. et al. Dual antiplatelet therapy after percutaneous coronary intervention and drug-eluting stents: a systematic review and network meta-analysis. Circulation 2020; 142 (15) 1425-1436
6 Kim HK, Tantry US, Smith Jr SC. et al. The East Asian paradox: an updated position statement on the challenges to the current antithrombotic strategy in patients with cardiovascular disease. Thromb Haemost 2021; 121 (04) 422-432
7 Gorog DA, Jeyalan V, Markides RIL, Navarese EP, Jeong YH, Farag M. Comparison of de-escalation of DAPT intensity or duration in East Asian and western patients with ACS undergoing PCI: a systematic review and meta-analysis. Thromb Haemost 2023; 123 (08) 773-792
8 Tricoci P, Huang Z, Held C. et al; TRACER Investigators. Thrombin-receptor antagonist vorapaxar in acute coronary syndromes. N Engl J Med 2012; 366 (01) 20-33
9 Verheugt FWA, Huber K. Continuous improvement of antiplatelet therapy in cardiovascular disease. Thromb Haemost 2023; 123 (02) 133-134
10 Théroux P, Ouimet H, McCans J. et al. Aspirin, heparin, or both to treat acute unstable angina. N Engl J Med 1988; 319 (17) 1105-1111
11 Hurlen M, Abdelnoor M, Smith P, Erikssen J, Arnesen H. Warfarin, aspirin, or both after myocardial infarction. N Engl J Med 2002; 347 (13) 969-974
12 Patel MR, Mahaffey KW, Garg J. et al; ROCKET AF Investigators. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365 (10) 883-891
13 Granger CB, Alexander JH, McMurray JJ. et al; ARISTOTLE Committees and Investigators. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365 (11) 981-992
14 Giugliano RP, Ruff CT, Braunwald E. et al; ENGAGE AF-TIMI 48 Investigators. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369 (22) 2093-2104
15 Goldin M, Koulas I, Weitz JI, Spyropoulos AC. State-of-the-art mini review: dual-pathway inhibition to reduce arterial and venous thromboembolism. Thromb Haemost 2022; 122 (08) 1279-1287
16 Galli M, Franchi F, Rollini F. et al. pharmacodynamic profiles of dual-pathway inhibition with or without clopidogrel versus dual antiplatelet therapy in patients with atherosclerotic disease. Thromb Haemost 2022; 122 (08) 1341-1351
17 Mega JL, Braunwald E, Wiviott SD. et al; ATLAS ACS 2–TIMI 51 Investigators. Rivaroxaban in patients with a recent acute coronary syndrome. N Engl J Med 2012; 366 (01) 9-19
18 Eikelboom JW, Connolly SJ, Bosch J. et al; COMPASS Investigators. Rivaroxaban with or without aspirin in stable cardiovascular disease. N Engl J Med 2017; 377 (14) 1319-1330
19 Ortega-Paz L, Franchi F, Rollini F. et al. Switching from dual antiplatelet therapy with aspirin plus a P2Y₁₂ inhibitor to dual pathway inhibition with aspirin plus vascular-dose rivaroxaban: the Switching Anti-Platelet and Anti-Coagulant Therapy (SWAP-AC) study. Thromb Haemost 2024; 124 (03) 263-273
20 Cimci M, Polad J, Mamas M. et al; e-ULTIMASTER investigators. Outcomes and regional differences in practice in a worldwide coronary stent registry. Heart 2022; 108 (16) 1310-1318